Still Ineffective When Added to Trikafta, Sionna Ends Development of Cystic Fibrosis Drug Candidate

For people with cystic fibrosis whose condition has already improved substantially with Trikafta, the next drug must demonstrate that it can push efficacy even further. Sionna Therapeutics’ SION-719 failed to clear that bar: a Phase 2a trial showed that adding it to Trikafta did not deliver the expected additional improvement in CFTR function.

Sionna said the PreciSION CF trial did not meet the key activity endpoint measured by a reduction in sweat chloride and therefore will not continue developing SION-719 as an add-on to standard treatment. The company also said it is reviewing factors that may have interfered with the results, but the information currently available publicly is insufficient to determine whether those factors would be enough to change the conclusion about the candidate.

The randomized, double-blind, placebo-controlled crossover trial enrolled adults who were stable on Trikafta and carried two copies of the F508del mutation; trial registry data listed an enrollment of 16 participants. The study primarily used sweat chloride concentration to assess CFTR ion-channel function, rather than directly examining clinical outcomes such as deterioration in lung function, acute exacerbations, or quality of life.

SION-719 was designed to stabilize NBD1, the first nucleotide-binding domain of the CFTR protein. The F508del mutation disrupts the stability of this domain, impairing the protein’s ability to fold, reach the cell surface, and maintain function. Sionna had hoped that this mechanism, which differs from that of existing modulators, could complement Trikafta, which consists of elexacaftor, tezacaftor, and ivacaftor.

However, demonstrating additional benefit in patients already receiving a highly effective standard treatment is inherently more difficult than comparing a therapy with placebo. This failure cannot, on the basis of a single small trial, invalidate the NBD1 stabilization strategy, but it shows that drug exposure and mechanistic signals observed in cellular and early human studies may not necessarily translate into a measurable add-on effect.

For Sionna, the impact also extends beyond a single trial. The company will evaluate measures to preserve capital, meaning that research and development priorities and other cystic fibrosis programs may be realigned. Because the full data, results from each treatment period, and safety details have not yet been disclosed, it is currently possible to confirm only that the Trikafta add-on path for SION-719 has ended; it is not yet possible to determine whether the failure resulted from the drug itself, the dose, the trial design, or a combination of factors.